Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
semaglutide + ALK7 siRNA
- Development stage
- Preclinical
- Lead developer
- Alnylam Pharmaceuticals
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptides
- Administration
- Subcutaneous
01
Overview
**Semaglutide + ALK7 siRNA** is an investigational combination regimen being evaluated for the treatment of obesity and metabolic disorders. The combination pairs semaglutide, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk, with an activin receptor-like kinase 7 (ALK7) small interfering RNA (siRNA) therapeutic (such as Arrowhead's ARO-ALK7, SanegeneBio's SGB-ALK7, or Alnylam's ALN-2232). Semaglutide primarily acts on the central nervous system to suppress appetite and reduce food intake, while the ALK7 siRNA selectively silences the expression of the *ACVR1C* gene in adipose tissue. ALK7 acts as a metabolic brake that suppresses lipolysis and promotes fat storage; silencing ALK7 enhances lipolysis and energy expenditure. Preclinical studies have demonstrated that combining ALK7 siRNA with semaglutide produces additive weight loss and fat mass reduction while significantly preserving lean muscle mass, addressing a key limitation of GLP-1 monotherapy.
- Other names
- semaglutide + ALK7 siRNAsemaglutide + ALN-2232semaglutide + ARO-ALK7semaglutide + SGB-ALK7semaglutide and ALK7 siRNAsemaglutide and ALN-2232semaglutide and ARO-ALK7semaglutide and SGB-ALK7semaglutide/ALK7 siRNA
02
Targets
ACVR1C (Activin A Receptor Type 1C)GLP1R (GLP-1R)
Beyond the preview
Go deeper on semaglutide + ALK7 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on semaglutide + ALK7 siRNA.